Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
High-throughput epigenomic profiling and epigenetic biomarkers
Innovative Solution
With a view to providing health management units as the basis for personalized medicine and contributing to improving women’s health, our first project’s goal is to develop an innovative molecular diagnostic test, which named as MPap DNA Methylation Detection Kit, that can be used for endometrial cancer.
About
Guzip Biomarkers Corporation is a 2018 spin-out company from Taipei Medical University. Guzip is a research-driven company looking forward to providing novel DNA methylation epigenetic biomarkers for applications in the clinic. With a view to providing health management units as the basis for personalized medicine and contributing to improving women’s health, our first project’s goal is to develop an innovative molecular diagnostic test, which named as MPapâ„¢ DNA Methylation Detection Kit, that can be used for endometrial cancer.
Products
Product
With a view to providing health management units as the basis for personalized medicine and contributing to improving women’s health, our first project’s goal is to develop an innovative molecular diagnostic test, which named as MPap DNA Methylation Detection Kit, that can be used for endometrial cancer.
Something missing or incorrect on this page? Help us enrich this information
